Industrial, technical and medical gases

Oversight and strategy. Remuneration and Benefits Committee member.

Strategy development & implementation. Profitability improvement. Sustainable product development & launches. Retail and industrial customer focus. Commercial excellence. Business oversight.

Primary responsibility for the Canada Operating Segment of Linde plc (operating under the name Praxair Canada) is setting the overall strategic direction for the segment. Report to the Head of Americas and regularly interface with the Company’s executive management team of Linde plc.Responsibilities include: - Long range strategic planning for the segment businesses - Analyze and approve financial and capital budgets - Monitor financial reports and execution of strategic business plans to meet profitability goals - Develop, enforce and evaluate business policies and procedures and influence Linde plc company-wide policies - Support the organization in securing business including meeting with key and potential customers - Look to the future for change opportunities including reviewing and advising on potential partnerships, alliances and acquisitions - Build and lead the executive teams within the segment - Model the company’s cultures, values and behaviors

Strategic and operational leadership of the region RME (Middle East, Eastern Europe, Russia) for the Linde Gas division, with full P&L responsibility. Managing a P&L of over 1B Euros, production & supply networks, CapEx investment in a region of dynamic economic and political environment through both organic and inorganic (M&A) growth opportunities, efficiency optimization, and productivity improvement.

Led Baxter's Hematology/Oncology business in Germany, Switzerland, Austria, Belgium, the Netherlands, Luxemburg, Poland, Czech Republic, Slovakia, Hungary, Romania, Bularia, Slovenia, Latvia, Estonia, Lithuania.Developed and implemented a new commercial organization in the region ahead of the Baxalta spin-off from Baxter.

In the UK/Ireland responsibilities included:- Provided operational business management for the BioScience division of the UK affiliate- Prepared and successfully re-launched the key Hemophilia brand, ADVATE, following the national rFVIII therapy tender win; tracking above budget since re-launch- Worked and directed work of teams with healthcare policymakers and payers; evaluated & initiated implementation of value-based procurement strategies, including risk-sharing schemes, aimed at shaping subsequent tenders- Assessed commercial opportunities and made recommendations as to launch pathway for a novel subcutaneous immunoglobulin agent for the treatment of Primary Immune Deficiency- Led teams to develop tender submission strategies, subsequently winning top awards of the tenders in homecare delivery in England/Wales and IG therapies in Scotland- Lead development of BioScience strategy and workforce planning in the UK affiliate, including in light of the imminent spinoff of the BioScience business- Advised on team structure for optimal go-to-market model; built high-performing cross-functional team- Liaised with the regional and global BioScience teams to represent the UK & Ireland clusterIn Deerfield, IL responsibilities included organizational design for new company in preparation for Baxter BioScience spin-off; driving alignment around a business model with a current JV partner in emerging markets, e.g. Turkey.

Developed and drove execution of the franchise strategic direction, focusing on the core platforms and key countries for growth, partnering of non-core assets for distribution, and ensuring success of recent acquisitions. Refocused the business on the core portfolio and its application areas of highest potential. Finalized acquisition of Synovis, a $80M+ annual revenue soft tissue repair company with 300 employees, drove its integration into Baxter, ensuring minimal disruption of the core business – two years post transaction, continuously exceeding the deal model. Drove geographic expansion for the core and recently acquired businesses. Successfully empowered and directed local affiliates to complete local strategic partner distribution agreements for non-core portfolio.Was promoted into the role.

Managed a global surgical portfolio of biological products and medical devices, drove geographic expansion into markets with highest growth potential, worked closely with affiliates on go-to-market strategies to determine portfolio mix, appropriate channel (direct/distribution), incentive structure to drive sustainable growth, peer-to-peer activities and surgeon education, marketing and planning support, and was actively involved in life cycle management and novel product development and launches.Was promoted into the role.

Managed a global surgical portfolio of biological products and medical devices, drove geographic expansion into markets with highest growth potential, worked closely with affiliates on go-to-market strategies to determine portfolio mix, appropriate channel (direct/distribution), incentive structure to drive sustainable growth, peer-to-peer activities and surgeon education, marketing and planning support, and was actively involved in life cycle management and novel product development and launches.Was promoted into the role.

Defined hemophilia treater decision-making and patient flow, determined significant opportunity for growth through co-positioning of the two therapies, highlighting unique advantages of FEIBA (longer half-life and possibility to provide prophylactic treatment to patients). Engaged closely with country affiliates to help define growth opportunities in terms of numbers of patients and treatment modalities. Forged strong relationships with the KOLs in the hemophilia community, and drove completion of a head-to-head study vs. recombinant competitor, which resulted in further highlighting the benefits of FEIBA.

Delivered a number of short- and long-term supply/demand scenarios to provide direction for supply chain and manufacturing. Drove market development to increase the rate of diagnosis and timely treatment of primary immune deficiency. Explored additional uses of IVIG and worked with the R&D and Clinical groups to initiate work on neurological studies in which IVIG showed promise in early-stage trials. Developed strong relationships with the KOLs and patient advocacy organizations to support treatment of rare immune system conditions.Was promoted into the role

Launched a rare disease compound intended to treat congenital protein C deficiency putting plans into place to build on the safety and efficacy data and expand its indications into the area of sepsis and multiple organ failure management for acute patients with multiple morbidities. Evaluated the feasibility of such studies and expected clinical success, presented findings to senior management. Drove commercial assessment and strategic fit of several monoclonal antibodies with the intent to enter co-development and add to the portfolio at a later stage.

Having relocated to the US from Germany, drove growth of the anti-infective business through launches of novel compounds, life cycle management of established brands, product co-positioning, and expansion into new segment of the market, such as long-term care, pediatric, and managed care.

Having relocated to the US from Germany, drove growth of the anti-infective business through launches of novel compounds, life cycle management of established brands, product co-positioning, and expansion into new segment of the market, such as long-term care, pediatric, and managed care.

Successfully completed a multi-phase management trainee program consisting of language and science training, sales, marketing, finance, and country manager’s rotations – in Germany.